Evaluation of Immune Response to AAV-Based Gene Therapy Products
With the advancement of life science technologies,gene therapy has emerged as a focal point in new drug development due to its specificity and precision.Among various vectors,adeno-associated virus(AAV)has gained prominence as an intracellular gene therapy vector,standing out as a hot research focus for gene therapy products.Currently,seven AAV-based gene therapy products have received regulatory approval and entered the market worldwide,and several clinical trials are underway.AAV vectors exhibit low immu-nogenicity,however,pre-existing immunity against AAV in certain populations may induce innate immune responses upon vector admin-istration.Subsequently,this may trigger adaptive immune reactions against the AAV capsid and transgene products,potentially influenc-ing the efficacy and safety of the therapeutic intervention.This review aims to outline the characteristics of immune responses induced by AAV-based gene therapy and briefly summarize the evaluation of immune response to AAV-based gene therapy in preclinical and clinical studies.The objective is to provide a reference for the evaluation of AAV-based gene therapy products.
Adeno-associated virus vectorAAVGene therapyEvaluation of immune response
万方数据
维普
